Clonidine (Catapresan)-double-blind study after long-term treatment with the drug in migraine.
A double-blind, cross-over study with clonidine (Catapresan) and placebo was carried out in 29 patients with migraine, who had received clonidine during a 4 to 32 months pre-test period (mean 10 months) and who appeared to have benefited from the treatment. Clonidine and placebo were given for 7 weeks each, but only the last 5 weeks in each period were used for the statistical evaluation. In the entire material, clonidine was significantly superior to placebo. In nine of the patients, however, various other factors might have influenced the attack frequency and severity. If these nine patients were excluded, no statistically significant difference between clonidine and placebo was found.
D000328:Adult; D002986:Clinical Trials as Topic; D003000:Clonidine / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D010919:Placebos; D013997:Time Factors
D010919:Placebos; D003000:Clonidine